Biohaven jumps as cancer treatment shows promise in early-stage trial

Shares of drugmaker Biohaven BHVN.N rise 8.5% to $11.50

Co says its experimental therapy, BHV-1510, in combination with Regeneron Pharmaceuticals' REGN.O Libtayo, showed efficacy and manageable safety across several tumors in an early-stage trial

Co says patients receiving the treatment every three weeks showed a 72.7% confirmed response

The combination therapy is being tested among pre-treated patients with advanced cancers - BHVN

RBC Capital Markets says it "sees these efficacy and safety results as promising"

Including session moves, stock down 69.2% YTD